Albert Kim, MD, PhD, is Vice President and Clinical Research Head for the Cardiovascular and Metabolic Disease Research Unit, he is an accomplished physician-scientist with broad expertise in cardiovascular disease, translational medicine, and drug development. Dr. Kim joined the Pfizer Cardiovasular and Metabolic Diseases Research Unit in 2013 and has served in multiple roles over the past three years leading early asset teams and contributing as a core member of the cardiovascular therapeutic area strategy team. Most recently, he was a co-Global Clinical Lead for the bococizumab Phase III program. In addition to project leadership experience, he has served in advisory and supervisory roles for cardiovascular safety and pharmacovigilance activities, and worked at the US Food and Drug Administration in the Division of Cardiac Devices as a medical reviewer and project lead for the industry guidance document on catheter ablation for atrial fibrillation. Dr. Kim earned his undergraduate degree in biomedical engineering from Harvard and MD and PhD degrees from University of California Los Angeles. He completed internal medicine residency at Brigham and Women's Hospital, cardiology fellowship training at Massachusetts General Hospital, and clinical electrophysiology training at University of California San Francisco. Prior to joining Pfizer, Dr. Kim joined the University of California San Francisco faculty and subsequently transitioned to the pharmaceutical industry as a Senior Translational Medicine Expert at Novartis, where he led small molecule and biologic asset programs for hyperlipidemia, inflammation, atherosclerosis, and arrhythmia indications. He holds academic appointments in the VA Boston Cardiac Electrophysiology Section, at Boston University, and at Harvard Medical School.
Clinical data management, Clinical trails, Pharmacovigilance